2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when trading near its 52-week low. There is plenty of room for struggling companies to dip further, so it's best to stay away from them, no matter how cheap they look.That's the situation both Tilray Brands (NASDAQ: TLRY) and Sarepta Therapeutics (NASDAQ: SRPT) find themselves in. Both stocks have significantly lagged broader equities this year and are hovering around 52-week lows. Despite the drop, they still aren't worth investing in. Here's what investors need to know about these two stocks.Image source: Getty Images.Continue reading
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when trading near its 52-week low. There is plenty of room for struggling companies to dip further, so it's best to stay away from them, no matter how cheap they look.
That's the situation both Tilray Brands (NASDAQ: TLRY) and Sarepta Therapeutics (NASDAQ: SRPT) find themselves in. Both stocks have significantly lagged broader equities this year and are hovering around 52-week lows. Despite the drop, they still aren't worth investing in. Here's what investors need to know about these two stocks.
Image source: Getty Images.
